PRaG therapy

An Innovative Hope for Pancreatic Cancer: A Case Study of PRaG 3.0 Therapy Pancreatic cancer is one of the deadliest forms of cancer, and when it spreads, it becomes even more difficult to treat. The prognosis for patients with advanced pancreatic ductal adenocarcinoma (PDAC) is often grim, with survival rates that are painfully low. Many…

Introduction: A New Hope for Metastatic Gastric Cancer Gastric cancer (GC) is one of the most common and deadly cancers globally, especially in countries like China, where it accounts for a significant percentage of cancer-related deaths. Approximately 20% of gastric cancer cases involve human epidermal growth factor receptor 2 (HER2) overexpression, a genetic abnormality that…

Introduction to Thyroid Hürthle Cell Carcinoma and Its Challenges Thyroid cancer is the most common type of endocrine cancer, and among its subtypes, Hürthle cell carcinoma (HCC) is rare but aggressive, accounting for 3-4% of all thyroid cancers. HCC is characterized by its poor prognosis due to its high risk of invasion and metastasis. Despite…

Metastatic triple-negative breast cancer (mTNBC) presents a formidable challenge due to its aggressive nature and poor prognosis. Despite numerous therapeutic approaches, such as surgery, chemotherapy, and radiotherapy, many patients with mTNBC experience treatment resistance. As survival rates remain low and options are limited for patients who have undergone multiple lines of therapy, the need for…

Cancer treatment is a field where no two journeys are the same. The case of advanced malignant perivascular epithelioid cell neoplasm (PEComa), as described in this report, brings to light the intricacies involved in treating rare cancers. PEComa, a rare and aggressive mesenchymal tumor, defies traditional treatment methods due to its rarity and unpredictability. What…

Introduction: The Ongoing Struggle Against Metastatic Colon Cancer As I read through the case of a metastatic colon cancer patient, it hit me how relentless and unforgiving this disease can be. The patient, a man in his mid-40s, had already gone through the usual treatments: chemotherapy, targeted therapies, and even palliative surgery. Yet, despite all…

Introduction: The Challenge of Platinum-Resistant Ovarian CancerOvarian cancer, particularly in its platinum-resistant form, remains one of the most challenging gynecologic cancers to treat. Typically diagnosed at advanced stages, ovarian cancer’s treatment protocol largely revolves around platinum-based chemotherapy. However, as resistance develops, particularly to platinum, survival rates significantly decrease, with limited therapeutic options available. Most standard…

Introduction: A New Hope for Refractory Metastatic ESCCEsophageal squamous cell carcinoma (ESCC) is a highly aggressive cancer with a poor prognosis, often diagnosed at an advanced stage. Traditional treatment options, including chemotherapy, often fail, especially in patients with metastatic disease. Despite advancements in immunotherapy, such as PD-1 inhibitors, their effectiveness in PD-L1-negative patients has been…

Introduction: A Breakthrough in Metastatic Gastric Cancer TreatmentGastric cancer, particularly when metastatic, often presents with a poor prognosis, especially when conventional therapies have failed. Patients who cannot tolerate chemotherapy due to organ dysfunction or a poor performance status face even fewer treatment options. A promising case report, PRaG Therapy of Refractory Metastatic Gastric Cancer, published…

Introduction: Overcoming Resistance in Cancer TreatmentCancer therapy has come a long way in recent years, with immunotherapies, such as PD-1 inhibitors, showing great promise. However, resistance to these treatments remains a significant hurdle. The case study titled PRaG regimens for rechallenge in a patient with acquired resistance to PD-1 inhibitor in advanced refractory renal pelvis…